Strategic Partnerships BB-031’s clinical profile as a rapid onset, reversible thrombolytic with a von Willebrand Factor target positions Basking for licensing or co development deals with large pharma and hospital networks pursuing AIS therapies.

Stroke Center Outreach Engage academic medical centers and integrated stroke networks for investigator led trials and early access programs to validate safety and efficacy, leveraging past conference exposure as credibility.

Funding Momentum Recent financing activity signals growth readiness; align BD efforts with manufacturing, CRO, and regulatory partners to support scale up and potential strategic alliances.

Technology Edge Emphasize BB-031's RNA based, rapid onset thrombolytic mechanism with a reversible profile to differentiate BB-031 from standard therapies and support competitive positioning.

Leadership Alignment Leverage the appointment of a new CEO to gain executive level interest; target partnership discussions with leadership to shape a growth roadmap, licensing, or joint ventures.